Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An International, Phase 3, Multicenter, Randomized, Open- Label Trial Comparing Balixafortide in Combination With Eribulin Versus Eribulin Alone in Patients With HER2 Negative, Locally Recurrent or Metastatic Breast Cancer

NCT03786094 is registered in ClinicalTrials.gov with Spexis AG as lead sponsor.

NCT NCT03786094
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03786094 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An International, Phase 3, Multicenter, Randomized, Open- Label Trial Comparing Balixafortide in Combination With Eribulin Versus Eribulin Alone in Patients With HER2 Negative, Locally Recurrent or Metastatic Breast Cancer
Lead sponsor
Spexis AG
Phase
Phase 3
Overall status
Terminated
Start date
May 30, 2019
Completion date
October 19, 2021
Enrollment
432 (actual)
Sites
88

Conditions

As the registry lists them; a condition with its own page is linked.

locally recurrent breast cancer, metastatic breast cancer